Non-clinical studies have shown that venlafaxine and its active metabolite O-desmethylvenlafaxine are strong inhibitors of 5-HT and NE reuptake and weak inhibitors of dopamine. In vitro tests have not found that venlafaxine and O-desmethylvenlafaxine have significant affinity for M cholinergic receptors, H1 histamine receptors, and α1-adrenergic receptors. Venlafaxine and O-desmethylvenlafaxine have no MAO inhibitory activity. Animal experiments have shown that venlafaxine has analgesic effects on pain models of mice or rats caused by acetic acid, brewer's yeast, and photothermal stimulation.

Non-clinical studies have shown that venlafaxine and its active metabolite O-desmethylvenlafaxine are strong inhibitors of 5-HT and NE reuptake and weak inhibitors of dopamine. In vitro tests have not found that venlafaxine and O-desmethylvenlafaxine have significant affinity for M cholinergic receptors, H1 histamine receptors, and α1-adrenergic receptors. Venlafaxine and O-desmethylvenlafaxine have no MAO inhibitory activity. Animal experiments have shown that venlafaxine has analgesic effects on pain models of mice or rats caused by acetic acid, brewer's yeast, and photothermal stimulation.

Selective 5-hydroxytryptamine 4 (5-HT4) receptor agonists promote the release of acetylcholine by stimulating the 5-HT4 receptors of the gastrointestinal cholinergic interneurons and myenteric plexus, thereby enhancing the motility of the upper gastrointestinal tract (stomach and small intestine). It has the effect of promoting gastric and duodenal motility and accelerating gastric emptying.

It is a smooth muscle relaxant. It has the function of inhibiting adenylate cyclase and phosphodiesterase, antagonizing calcium ions, and has a weak antimuscarinic effect. It has a selective spasmolytic effect on the smooth muscles of the urogenital system, and can directly relieve the spasm of the smooth muscles of the urogenital system, relax the muscles, and eliminate the lower abdominal pain caused by frequent urination, urgency, urinary incontinence, and spasm of the urethral bladder smooth muscles.

This product is a selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. It promotes the release of acetylcholine by stimulating the 5-HT4 receptors of the gastrointestinal cholinergic interneurons and myenteric plexus, thereby enhancing gastrointestinal motility and improving the gastrointestinal symptoms of patients with functional dyspepsia without affecting the secretion of gastric acid. This product has no affinity with dopamine D2, 5-HT1, and 5-HT2 receptors on the brain synaptic membrane, so there are no extrapyramidal side effects caused by the blockade of these receptors.